Sling Therapeutics, Inc.
A clinical-stage biotechnology company developing an oral drug candidate for thyroid eye disease.
$123MSeries C
LeadF
Forbion
Activity from announced rounds
Activity in this selectionceline-lazorthes-f8222807
- Rounds participated in
- 2
- Confirmed lead rounds
- 1 All roles disclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $348M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionSolstice Oncology
A clinical-stage immunotherapy company is advancing an engineered CTLA-4 antibody for earlier cancer treatment.
$225MSeries A
Participant